Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Key Laboratory Cardio-Cerebral Vessel Collateral Disease, State Administration of Traditional Chinese Medicine, Shijiazhuang, 050023, Hebei, China.
J Cardiovasc Transl Res. 2023 Feb;16(1):127-140. doi: 10.1007/s12265-022-10277-2. Epub 2022 May 26.
Heart failure with preserved ejection fraction (HFpEF) is a common public health problem associated with increased morbidity and long-term mortality. However, effective treatment for HFpEF was not discovered yet. In the present study, we aimed to decipher the effects of Periplocin on DOCA-induced heart failure rats and explore the possible underlying mechanisms. We demonstrated that Periplocin could significantly attenuate cardiac structural remodeling and improve cardiac diastolic function. Of note, Periplocin significantly inhibited the recruitment of inflammatory and immune cells and decreased the expression of serum inflammatory cytokines. Meanwhile, Periplocin had the effect of cardiac glycosides to improve cardiomyocyte contractility and calcium transient amplitude. These findings indicate that Periplocin might be a potential medicine to treat HFpEF in patients.
射血分数保留型心力衰竭（HFpEF）是一种常见的公共健康问题，与发病率和长期死亡率的增加有关。然而，目前尚未发现治疗 HFpEF 的有效方法。在本研究中，我们旨在探讨杠柳毒苷对 DOCA 诱导的心力衰竭大鼠的作用及其可能的机制。研究结果表明，杠柳毒苷可显著减轻心脏结构重构，改善心脏舒张功能。值得注意的是，杠柳毒苷可显著抑制炎症和免疫细胞的募集，降低血清炎症细胞因子的表达。同时，杠柳毒苷具有强心苷样作用，可改善心肌细胞的收缩力和钙瞬变幅度。这些发现表明，杠柳毒苷可能是治疗 HFpEF 患者的一种潜在药物。
